1932
0
  1. Home
  2. A-Z Publications
  3. Annual Review of Medicine
  4. Volume 74, 2023
  5. Article

Annual Review of Medicine

Volume 74, 2023

Primary Aldosteronism and the Role of Mineralocorticoid Receptor Antagonists for the Heart and Kidneys

Abstract

Primary aldosteronism (PA) is the most common cause of secondary hypertension but is frequently underrecognized and undertreated. Patients with PA are at a markedly increased risk for target organ damage to the heart and kidneys. While patients with unilateral PA can be treated surgically, many patients with PA are not eligible or willing to undergo surgery. Steroidal mineralocorticoid receptor antagonists (MRAs) are highly effective for treating PA and reducing the risk of target organ damage. However, steroidal MRAs are often underprescribed and can be poorly tolerated by some patients due to side effects. Nonsteroidal MRAs reduce adverse renal and cardiovascular outcomes among patients with diabetic kidney disease and are bettertolerated than steroidal MRAs. While their blood pressure–lowering effects remain unclear, these agents may have a potential role in reducing target organ damage in patients with PA.

Keyword(s): cardiovascular disease, chronic kidney disease, hypertension, mineralocorticoid receptor antagonists, primary aldosteronism
Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-042921-100438
2023-01-27
2024-04-30
Loading full text...

Full text loading...

/deliver/fulltext/med/74/1/annurev-med-042921-100438.html?itemId=/content/journals/10.1146/annurev-med-042921-100438&mimeType=html&fmt=ahah

Literature Cited

  1. 1.
    Whelton PK, Carey RM, Aronow WS et al. 2018. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 71:1269–324
     [Google Scholar]
  2. 2.
    Muntner P, Hardy ST, Fine LJ et al. 2020. Trends in blood pressure control among US adults with hypertension, 1999–2000 to 2017–2018. JAMA 324:1190–200
     [Google Scholar]
  3. 3.
    Zhou B, Carrillo-Larco RM, Danaei G et al. 2021. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet 398:957–80
     [Google Scholar]
  4. 4.
    Brown JM, Siddiqui M, Calhoun DA et al. 2020. The unrecognized prevalence of primary aldosteronism. Ann. Intern. Med. 173:10–20
     [Google Scholar]
  5. 5.
    Funder JW, Carey RM, Mantero F et al. 2016. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 101:1889–916
     [Google Scholar]
  6. 6.
    Cohen JB, Cohen DL, Herman DS et al. 2021. Testing for primary aldosteronism and mineralocorticoid receptor antagonist use among U.S. veterans: a retrospective cohort study. Ann. Intern. Med. 174:289–97
     [Google Scholar]
  7. 7.
    Hundemer GL, Imsirovic H, Vaidya A et al. 2022. Screening rates for primary aldosteronism among individuals with hypertension plus hypokalemia: a population-based retrospective cohort study. Hypertension 79:178–86
     [Google Scholar]
  8. 8.
    Lim PO, Jung RT, MacDonald TM. 1999. Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study. Br. J. Clin. Pharmacol. 48:756–60
     [Google Scholar]
  9. 9.
    Williams B, MacDonald TM, Morant S et al. 2015. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 386:2059–68
     [Google Scholar]
  10. 10.
    Rossi GP, Sacchetto A, Visentin P et al. 1996. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 27:1039–45
     [Google Scholar]
  11. 11.
    Monticone S, Burrello J, Tizzani D et al. 2017. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J. Am. Coll. Cardiol. 69:1811–20
     [Google Scholar]
  12. 12.
    Milliez P, Girerd X, Plouin PF et al. 2005. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J. Am. Coll. Cardiol. 45:1243–48
     [Google Scholar]
  13. 13.
    Redheuil A, Blanchard A, Pereira H et al. 2020. Aldosterone-related myocardial extracellular matrix expansion in hypertension in humans: a proof-of-concept study by cardiac magnetic resonance. JACC Cardiovasc. Imaging 13:2149–59
     [Google Scholar]
  14. 14.
    Chen ZW, Huang KC, Lee JK et al. 2018. Aldosterone induces left ventricular subclinical systolic dysfunction: a strain imaging study. J. Hypertens. 36:353–60
     [Google Scholar]
  15. 15.
    Cesari M, Letizia C, Angeli P et al. 2016. Cardiac remodeling in patients with primary and secondary aldosteronism: a tissue Doppler study. Circ. Cardiovasc. Imaging 9:e004815
     [Google Scholar]
  16. 16.
    Ohno Y, Sone M, Inagaki N et al. 2018. Prevalence of cardiovascular disease and its risk factors in primary aldosteronism: a multicenter study in Japan. Hypertension 71:530–37
     [Google Scholar]
  17. 17.
    Born-Frontsberg E, Reincke M, Rump LC et al. 2009. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry. J. Clin. Endocrinol. Metab. 94:1125–30
     [Google Scholar]
  18. 18.
    Fernandez-Argueso M, Pascual-Corrales E, Bengoa Rojano N et al. 2021. Higher risk of chronic kidney disease and progressive kidney function impairment in primary aldosteronism than in essential hypertension. Case-control study. Endocrine 73:439–46
     [Google Scholar]
  19. 19.
    Savard S, Amar L, Plouin PF, Steichen O. 2013. Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. Hypertension 62:331–36
     [Google Scholar]
  20. 20.
    Mulatero P, Monticone S, Bertello C et al. 2013. Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. J. Clin. Endocrinol. Metab. 98:4826–33
     [Google Scholar]
  21. 21.
    Catena C, Colussi G, Nadalini E et al. 2008. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch. Intern. Med. 168:80–85
     [Google Scholar]
  22. 22.
    Burrello J, Monticone S, Losano I et al. 2020. Prevalence of hypokalemia and primary aldosteronism in 5100 patients referred to a tertiary hypertension unit. Hypertension 75:1025–33
     [Google Scholar]
  23. 23.
    Hundemer GL, Curhan GC, Yozamp N et al. 2018. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol 6:51–59
     [Google Scholar]
  24. 24.
    Monticone S, D'Ascenzo F, Moretti C et al. 2018. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 6:41–50
     [Google Scholar]
  25. 25.
    Murata M, Kitamura T, Tamada D et al. 2017. Plasma aldosterone level within the normal range is less associated with cardiovascular and cerebrovascular risk in primary aldosteronism. J. Hypertens. 35:1079–85
     [Google Scholar]
  26. 26.
    Monticone S, Sconfienza E, D'Ascenzo F et al. 2020. Renal damage in primary aldosteronism: a systematic review and meta-analysis. J. Hypertens. 38:3–12
     [Google Scholar]
  27. 27.
    Kawashima A, Sone M, Inagaki N et al. 2019. Renal impairment is closely associated with plasma aldosterone concentration in patients with primary aldosteronism. Eur. J. Endocrinol. 181:339–50
     [Google Scholar]
  28. 28.
    Sechi LA, Novello M, Lapenna R et al. 2006. Long-term renal outcomes in patients with primary aldosteronism. JAMA 295:2638–45
     [Google Scholar]
  29. 29.
    Hundemer GL, Curhan GC, Yozamp N et al. 2018. Renal outcomes in medically and surgically treated primary aldosteronism. Hypertension 72:658–66
     [Google Scholar]
  30. 30.
    Jaffe G, Gray Z, Krishnan G et al. 2020. Screening rates for primary aldosteronism in resistant hypertension: a cohort study. Hypertension 75:650–59
     [Google Scholar]
  31. 31.
    Ruhle BC, White MG, Alsafran S et al. 2019. Keeping primary aldosteronism in mind: deficiencies in screening at-risk hypertensives. Surgery 165:221–27
     [Google Scholar]
  32. 32.
    Sivarajah M, Beninato T, Fahey TJ 3rd. 2020. Adherence to consensus guidelines for screening of primary aldosteronism in an urban healthcare system. Surgery 167:211–15
     [Google Scholar]
  33. 33.
    Velagaleti RS, Gona P, Levy D et al. 2008. Relations of biomarkers representing distinct biological pathways to left ventricular geometry. Circulation 118:2252–58
     [Google Scholar]
  34. 34.
    Inoue K, Goldwater D, Allison M et al. 2020. Serum aldosterone concentration, blood pressure, and coronary artery calcium: the Multi-Ethnic Study of Atherosclerosis. Hypertension 76:113–20
     [Google Scholar]
  35. 35.
    Deo R, Yang W, Khan AM et al. 2014. Serum aldosterone and death, end-stage renal disease, and cardiovascular events in blacks and whites: findings from the Chronic Renal Insufficiency Cohort (CRIC) study. Hypertension 64:103–10
     [Google Scholar]
  36. 36.
    Tomaschitz A, Pilz S, Ritz E et al. 2010. Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Eur. Heart J. 31:1237–47
     [Google Scholar]
  37. 37.
    Marzano L, Colussi G, Sechi LA, Catena C. 2015. Adrenalectomy is comparable with medical treatment for reduction of left ventricular mass in primary aldosteronism: meta-analysis of long-term studies. Am. J. Hypertens. 28:312–18
     [Google Scholar]
  38. 38.
    Satoh M, Maruhashi T, Yoshida Y, Shibata H. 2019. Systematic review of the clinical outcomes of mineralocorticoid receptor antagonist treatment versus adrenalectomy in patients with primary aldosteronism. Hypertens. Res. 42:817–24
     [Google Scholar]
  39. 39.
    Brown JJ, Davies DL, Ferriss JB et al. 1972. Comparison of surgery and prolonged spironolactone therapy in patients with hypertension, aldosterone excess, and low plasma renin. BMJ 2:729–34
     [Google Scholar]
  40. 40.
    Chen C, Zhu XY, Li D et al. 2020. Clinical efficacy and safety of spironolactone in patients with resistant hypertension: a systematic review and meta-analysis. Medicine 99:e21694
     [Google Scholar]
  41. 41.
    Carey RM, Calhoun DA, Bakris GL et al. 2018. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension 72:e53–e90
     [Google Scholar]
  42. 42.
    Egan BM, Zhao Y, Axon RN et al. 2011. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation 124:1046–58
     [Google Scholar]
  43. 43.
    Fontil V, Pletcher MJ, Khanna R et al. 2014. Physician underutilization of effective medications for resistant hypertension at office visits in the United States: NAMCS 2006–2010. J. Gen. Intern. Med. 29:468–76
     [Google Scholar]
  44. 44.
    Hwang AY, Dave C, Smith SM 2016. Trends in antihypertensive medication use among US patients with resistant hypertension, 2008 to 2014. Hypertension 68:1349–54
     [Google Scholar]
  45. 45.
    Agarwal R, Kolkhof P, Bakris G et al. 2021. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur. Heart J. 42:152–61
     [Google Scholar]
  46. 46.
    Amazit L, Le Billan F, Kolkhof P et al. 2015. Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1. J. Biol. Chem. 290:21876–89
     [Google Scholar]
  47. 47.
    Kolkhof P, Delbeck M, Kretschmer A et al. 2014. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J. Cardiovasc. Pharmacol. 64:69–78
     [Google Scholar]
  48. 48.
    Lentini S, Heinig R, Kimmeskamp-Kirschbaum N, Wensing G. 2016. Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone—results from first-in-man and relative bioavailability studies. Fundam. Clin. Pharmacol. 30:172–84
     [Google Scholar]
  49. 49.
    Gerisch M, Heinig R, Engelen A et al. 2018. Biotransformation of finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, in dogs, rats, and humans, in vivo and in vitro. Drug Metab. Dispos. 46:1546–55
     [Google Scholar]
  50. 50.
    Grune J, Beyhoff N, Smeir E et al. 2018. Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone's antifibrotic activity. Hypertension 71:599–608
     [Google Scholar]
  51. 51.
    Montalescot G, Pitt B, Lopez de Sa E et al. 2014. Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study. Eur. Heart J. 35:2295–302
     [Google Scholar]
  52. 52.
    Pitt B, Zannad F, Remme WJ et al. 1999. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 341:709–17
     [Google Scholar]
  53. 53.
    Sehgal R, Singh H, Singh IP. 2020. Comparative study of spironolactone and eplerenone in management of ascites in patients of cirrhosis of liver. Eur. J. Gastroenterol. Hepatol. 32:535–39
     [Google Scholar]
  54. 54.
    FDA 2008. Highlights of prescribing information: Inspra (eplerenone) tablets. https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021437s006lbl.pdf
  55. 55.
    Dojki FK, Bakris G. 2017. Nonsteroidal mineralocorticoid antagonists in diabetic kidney disease. Curr. Opin. Nephrol. Hypertens. 26:368–74
     [Google Scholar]
  56. 56.
    Pitt B, Kober L, Ponikowski P et al. 2013. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94–8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur. Heart J. 34:2453–63
     [Google Scholar]
  57. 57.
    Filippatos G, Anker SD, Bohm M et al. 2016. A randomized controlled study of finerenone versus eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur. Heart J. 37:2105–14
     [Google Scholar]
  58. 58.
    Zhang MZ, Bao W, Zheng QY et al. 2022. Efficacy and safety of finerenone in chronic kidney disease: a systematic review and meta-analysis of randomized clinical trials. Front. Pharmacol. 13:819327
     [Google Scholar]
  59. 59.
    Fourkiotis V, Vonend O, Diederich S et al. 2013. Effectiveness of eplerenone or spironolactone treatment in preserving renal function in primary aldosteronism. Eur. J. Endocrinol. 168:75–81
     [Google Scholar]
  60. 60.
    Matsuda Y, Kawate H, Matsuzaki C et al. 2016. Eplerenone improves carotid intima-media thickness (IMT) in patients with primary aldosteronism. Endocr. J. 63:249–55
     [Google Scholar]
  61. 61.
    Rossi GP, Maiolino G, Flego A et al. 2018. Adrenalectomy lowers incident atrial fibrillation in primary aldosteronism patients at long term. Hypertension 71:585–91
     [Google Scholar]
  62. 62.
    Wu VC, Wang SM, Huang KH et al. 2021. Long-term mortality and cardiovascular events in patients with unilateral primary aldosteronism after targeted treatments. Eur. J. Endocrinol. 186:195–205
     [Google Scholar]
  63. 63.
    Hundemer GL, Curhan GC, Yozamp N et al. 2018. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol 6:51–59
     [Google Scholar]
  64. 64.
    Hundemer GL, Curhan GC, Yozamp N et al. 2018. Incidence of atrial fibrillation and mineralocorticoid receptor activity in patients with medically and surgically treated primary aldosteronism. JAMA Cardiol 3:768–74
     [Google Scholar]
  65. 65.
    Tezuka Y, Turcu AF. 2021. Real-world effectiveness of mineralocorticoid receptor antagonists in primary aldosteronism. Front. Endocrinol. 12:625457
     [Google Scholar]
  66. 66.
    Nakano Y, Yoshimoto T, Fukuda T et al. 2018. Effect of eplerenone on the glomerular filtration rate (GFR) in primary aldosteronism: sequential changes in the GFR during preoperative eplerenone treatment to subsequent adrenalectomy. Intern. Med. 57:2459–66
     [Google Scholar]
  67. 67.
    Kobayashi H, Abe M, Nakamura Y et al. 2019. Association between acute fall in estimated glomerular filtration rate after treatment for primary aldosteronism and long-term decline in renal function. Hypertension 74:630–38
     [Google Scholar]
  68. 68.
    Iwakura Y, Morimoto R, Kudo M et al. 2014. Predictors of decreasing glomerular filtration rate and prevalence of chronic kidney disease after treatment of primary aldosteronism: renal outcome of 213 cases. J. Clin. Endocrinol. Metab. 99:1593–98
     [Google Scholar]
  69. 69.
    Kim KJ, Hong N, Yu MH et al. 2021. Time-dependent risk of atrial fibrillation in patients with primary aldosteronism after medical or surgical treatment initiation. Hypertension 77:1964–73
     [Google Scholar]
  70. 70.
    Holaj R, Rosa J, Zelinka T et al. 2015. Long-term effect of specific treatment of primary aldosteronism on carotid intima-media thickness. J. Hypertens. 33:874–82
     [Google Scholar]
  71. 71.
    Bauersachs J, Jaisser F, Toto R. 2015. Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases. Hypertension 65:257–63
     [Google Scholar]
  72. 72.
    Luther JM, Fogo AB. 2022. The role of mineralocorticoid receptor activation in kidney inflammation and fibrosis. Kidney Int. Suppl. 12:63–68
     [Google Scholar]
  73. 73.
    Edwards NC, Steeds RP, Stewart PM et al. 2009. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. J. Am. Coll. Cardiol. 54:505–12
     [Google Scholar]
  74. 74.
    Kalizki T, Schmidt BMW, Raff U et al. 2017. Low dose-eplerenone treatment decreases aortic stiffness in patients with resistant hypertension. J. Clin. Hypertens. 19:669–76
     [Google Scholar]
  75. 75.
    Aryal SR, Siddiqui M, Sharifov OF et al. 2021. Spironolactone reduces aortic stiffness in patients with resistant hypertension independent of blood pressure change. J. Am. Heart Assoc. 10:e019434
     [Google Scholar]
  76. 76.
    Pitt B, Remme W, Zannad F et al. 2003. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348:1309–21
     [Google Scholar]
  77. 77.
    Zannad F, McMurray JJ, Krum H et al. 2011. Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 364:11–21
     [Google Scholar]
  78. 78.
    Zannad F, Alla F, Dousset B et al. 2000. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES). Circulation 102:2700–6
     [Google Scholar]
  79. 79.
    Iraqi W, Rossignol P, Angioi M et al. 2009. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Circulation 119:2471–79
     [Google Scholar]
  80. 80.
    Writing C, Maddox TM, Januzzi JL Jr. et al. 2021. 2021 Update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee. J. Am. Coll. Cardiol. 77:772–810
     [Google Scholar]
  81. 81.
    de Denus S, O'Meara E, Desai AS et al. 2017. Spironolactone metabolites in TOPCAT—new insights into regional variation. N. Engl. J. Med. 376:1690–92
     [Google Scholar]
  82. 82.
    Pfeffer MA, Claggett B, Assmann SF et al. 2015. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation 131:34–42
     [Google Scholar]
  83. 83.
    Edelmann F, Wachter R, Schmidt AG et al. 2013. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 309:781–91
     [Google Scholar]
  84. 84.
    Pitt B, Pfeffer MA, Assmann SF et al. 2014. Spironolactone for heart failure with preserved ejection fraction. N. Engl. J. Med. 370:1383–92
     [Google Scholar]
  85. 85.
    Georgianos PI, Agarwal R. 2021. Mineralocorticoid receptor antagonism in chronic kidney disease. Kidney Int. Rep. 6:2281–91
     [Google Scholar]
  86. 86.
    Bianchi S, Bigazzi R, Campese VM. 2006. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 70:2116–23
     [Google Scholar]
  87. 87.
    Savarese G, Carrero JJ, Pitt B et al. 2018. Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry. Eur. J. Heart Fail. 20:1326–34
     [Google Scholar]
  88. 88.
    Jarjour M, Henri C, de Denus S et al. 2020. Care gaps in adherence to heart failure guidelines: clinical inertia or physiological limitations?. JACC Heart Fail 8:725–38
     [Google Scholar]
  89. 89.
    Petrak O, Zelinka T, Strauch B et al. 2016. Combination antihypertensive therapy in clinical practice. The analysis of 1254 consecutive patients with uncontrolled hypertension. J. Hum. Hypertens. 30:35–39
     [Google Scholar]
  90. 90.
    Chung EYM, Strippoli GFM. 2021. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of CKD: editorial summary of a Cochrane review. Am. J. Kidney Dis. 77:810–12
     [Google Scholar]
  91. 91.
    Weir MR, Bakris GL, Bushinsky DA et al. 2015. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N. Engl. J. Med. 372:211–21
     [Google Scholar]
  92. 92.
    Bakris GL, Agarwal R, Anker SD et al. 2020. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N. Engl. J. Med. 383:2219–29
     [Google Scholar]
  93. 93.
    Pitt B, Filippatos G, Agarwal R et al. 2021. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N. Engl. J. Med. 385:2252–63
     [Google Scholar]
  94. 94.
    Am. Diabetes Assoc. Prof. Pract. Comm 2022. Erratum. 11. Chronic kidney disease and risk management: standards of medical care in diabetes—2022. Diabetes Care 2022;45(Suppl. 1):S175–S184. Diabetes Care 45:758
     [Google Scholar]
  95. 95.
    Kolkhof P, Barfacker L. 2017. 30 Years of the mineralocorticoid receptor: mineralocorticoid receptor antagonists: 60 years of research and development. J. Endocrinol. 234:T125–40
     [Google Scholar]
  96. 96.
    Epstein M. 2021. Aldosterone and mineralocorticoid receptor signaling as determinants of cardiovascular and renal injury: from Hans Selye to the present. Am. J. Nephrol. 52:209–16
     [Google Scholar]
/content/journals/10.1146/annurev-med-042921-100438
Loading
Primary Aldosteronism and the Role of Mineralocorticoid Receptor Antagonists for the Heart and Kidneys
Annual Review of Medicine 74, 217 (2023); https://doi.org/10.1146/annurev-med-042921-100438
/content/journals/10.1146/annurev-med-042921-100438
/content/journals/10.1146/annurev-med-042921-100438
Loading

Data & Media loading...

  • Article Type: Review Article

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error